Gout is a metabolic disorder of purine metabolism that results in crystallization of uric acid in the form of monosodium urate crystals, affects 8.3 million Americans and is the most common cause of inflammatory arthritis in adults. Urate lowering therapy is the mainstay of treatment for chronic gout. Initial treatments of choice in gout include allopurinol, a purine analog which inhibits xanthine oxidase and decreases the production of uric acid as well as probenecid which increases the urinary excretion of uric acid. However, 3% of patients will fail these treatments. In 2010, pegloticase, a recombinant urate oxidase conjugated to polyethylene glycol, was approved for these patients. Pegloticase has been shown to rapidly normalize plasma uric acid values, resolve tophi and improve quality of life in these patients. Hereby we present a case of a 50-yearold African male admitted to the hospital with symptomatic anemia 1 week after pegloticase infusion. He was found to have glucose-6-phosphate dehydrogenase deficiency, predisposing him to hemolytic anemia. Hereby we discuss his clinical course, and suggest glucose-6-phosphate dehydrogenase deficiency screening prior to pegloticase infusion.
Introduction
Pegloticase is a recombinant urate oxidase conjugated to polyethylene glycol (PEG) that is approved for management of chronic refractory gout after failure of conventional uratelowering therapies (ULTs) (i.e., allopurinol, febuxostat or probenecid) [1] . Although pegloticase has been shown to rapidly normalize plasma uric acid (PUA) values, resolve tophi and improve quality of life and function in these patients, a thorough understanding of its adverse reactions is lacking. We hereby present a case of hemolytic anemia induced by pegloticase in patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency [2] [3] [4] .
Case Report
A 50-year-old African American male with a medical history of hypertension, gout and rheumatoid arthritis presented to outpatient clinic complaining progressively worsening dyspnea over a course of a week. The patient was found to have an oxygen saturation of 92% with concomitant anemia and was immediately referred to the emergency department (ED). In the ED, the patient endorsed intermittent dyspnea and complained of "tea colored urine" that had begun approximately 2 days after starting a new medication for his uncontrolled gout, pegloticase. His home medications included amlodipine (10 mg/day), aspirin (81 mg/day), carvedilol (3.125 mg/day) and methotrexate (10 mg/week). He was then admitted to the general medicine ward for further evaluation and management of his anemia.
On examination, the patient's oxygen saturation was 92% on room air and other vital signs were within normal limits. His jugular venous pressure waveform was not elevated, and his cardiopulmonary examination was normal. No hepatosplenomegaly was appreciated, nor abdominal or suprapubic tenderness. He had no lower extremity edema and no stigmata suggestive of chronic liver disease. The neurological examination was normal. His initial labs were significant for hyponatremia (132 mmol/L), elevated blood urea nitrogen (BUN) (25 mmol/L), normal creatinine (0.85 mg/dL), elevated direct bilirubin (0.9 mg/dL) and total bilirubin (4.2 mg/dL), as was the patient's lactate dehydrogenase (876 U/L). The patient's complete blood count revealed leukocytosis (16.9 × 10 3 /mm 3 ), and macrocytic anemia with a hemoglobin of 7.3 g/dL, hematocrit of 24.2%, mean corpuscular volume of 101.7 fL, and red cell distribution width was elevated at 16%. He did have an elevated D-dimer (3.1 mg/L) and fibrinogen activity (523 mg/ dL) with normal coagulation studies. Further testing showed low haptoglobin (17 mg/dL), and normal vitamin B12 and folate levels. Urinalysis was remarkable for a large amount of hemoglobin, 2+ protein and 2+ urobilogen with < 1 red blood cell per high powered field and the urine myoglobin was significantly elevated at 814 ng/mL.
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and pelvis with IV contrast was obtained which revealed colonic diverticulosis, hepatic steatosis and avascular necrosis of the femoral heads. A chest CT with IV contrast did not show any signs of pulmonary embolism. To better define this presumable hemolytic anemia, further tests were done and revealed normal red blood cell folate hemolysate and creatine phosphokinase, negative direct Coombs test and peripheral blood smear that failed to show significant anisopoikilocytosis or abnormal red blood cell (Fig. 1) . However, quantitative G6PD was 194, and red blood cell G6PD was low at 2.14 × 10 6 (normal range: 4.14 × 10 6 -5.80 × 10 6 ), confirming a diagnosis of hemolytic anemia with G6PD deficiency. Patient was managed with IV hydration (which resolved both the patient's hyponatremia and elevated BUN) and required transfusion of 3 packed RBC units. After 4 days spent on the medicine ward, patient's symptoms resolved, and the patient was discharged home.
Discussion
To our knowledge, this is the third case of hemolytic anemia triggered by pegloticase in patients with G6PD deficiency [5, 6] . Pegloticase actively converts urate to allantoin, a more soluble end product of purine metabolism. During this process hydrogen peroxide is generated and creates an oxidative insult that triggers hemolysis in predisposed patients, such as those with G6PD deficiency. Patients with G6PD deficiency were excluded from initial trials of pegloticase due to a potential predisposition for hemolysis under oxidative stressors. G6PD is the only source of reduced glutathione in a red blood cell that mediates oxidative stress. This enzymatic deficiency affects approximately 400 million people worldwide [7] . In the USA, epidemiological studies have suggested that as many as 13% of African American males possess G6PD deficiency [8] . Therefore, we recommend screening for G6PD deficiency prior to pegloticase initiation. Finally, if a patient experience hemolytic anemia after pegloticase infusion, supportive treatment with red blood cell infusions should be initiated and plasmapheresis may be required given pegloticase's 14-day halflife [9] .
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